Merck Message Board - Msg: 3717235

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck

MRK 100.33

+1.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bernie Goldberg who wrote (649)	3/15/1998 2:30:00 PM
From: Mephisto	Read Replies (2) of 1580

I think investors have become more sophisticated. They want to invest in proven drug companies instead of taking chances on tiny little companies that do not have a product or if the company has a product the investor may not understand the consequences of that product. I also think Americans are beginning to think about management b4 they buy shares. Most everyone has seen what has happened in the mutual fund sector when managers skip from one fund to another. It can be a disaster for the investor. On the other hand, a new fund manager might make great profits for an investor. The problem: you never know. For example, Boeing is a company with bad management. Most companies would think they were in heaven if they had as many orders as Boeing. But what happened? Boeing management screwed up. They did not ramp up their orders for parts and they did not train their workers as quickly as they should have. I have shares in Boeing so that is why I feel like I can criticize the company. I hope shareholders fire the current management. By contrast, Merck is a company that is managed very, very well. Geez! I am chatty for a Sunday morning! Here is an article that compares the biotech firms with the drug companies. "By contrast, the drug group with Merck (NYSE:MRK - news), Warner-Lambert (NYSE:WLA - news),Abbott Laboratories (NYSE:ABT - news), Schering-Plough (NYSE:SGP - news) and Pfizer (NYSE:PFE - news) -- which many times drive development at biotechnology firms -- has soared 18.5% since January." The article's point was that overall biotechs have not fared as well on the market as the major drug companies. I hope the weather is nice & you have a nice Sunday!!! Mephisto

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next